- On April 23, 2026, the U.S. Department of Justice issued a final order moving state-licensed medical marijuana and FDA-approved marijuana products from Schedule I to Schedule III of the Controlled Substances Act. That's the biggest federal shift on cannabis in over 50 years.
- It is partial. Adult-use (recreational) cannabis and synthetic THC stay on Schedule I for now. A separate DEA administrative hearing on rescheduling the rest began June 29, 2026 and was set to wrap up around July 15, 2026 — with no final decision on that piece yet.
- For an everyday Vermont shopper, nothing at the register changes. You're still 21+, you still show ID, you still pay Vermont's 14% excise plus 6% sales tax (about 20% statewide, 21% in Burlington), and cannabis still can't be consumed in public or carried across state lines.
- The move is mostly a federal tax and research story for the industry — not a price cut or a legalization of recreational weed. And it's separate from Vermont's own medical-use endorsement, which is a state program with its own tax-free benefit for registered patients.
If you saw a headline in late April saying marijuana was reclassified — or moved to Schedule III — you weren't misreading it. On April 23, 2026, the U.S. Department of Justice issued a final order rescheduling part of the cannabis world under federal law. It's a genuinely historic change. It's also narrower than most headlines made it sound, and for someone buying a pre-roll on Church Street, the practical effect is close to zero. Here's the plain-English version of what moved, what stayed put, and what it means in Vermont.
What actually changed on April 23, 2026?
The federal government sorts controlled substances into five "schedules" under the Controlled Substances Act. Schedule I is the most restrictive tier — reserved, on paper, for substances the government treats as having no accepted medical use. Cannabis had sat there since 1970. The DOJ's April 23 final order moved a specific slice of it — state-licensed medical marijuana and FDA-approved marijuana products — down to Schedule III, the same federal tier as things like ketamine and certain codeine combinations.
In legal terms, that's a large statement: it's the federal government formally recognizing an accepted medical use and a lower abuse potential for those products. The order and its reasoning are laid out in the DOJ's Office of Public Affairs announcement and the corresponding notice in the Federal Register (document 2026-08177). If you want the primary sources rather than a summary, those are the two to read.
So is marijuana legal federally now?
No. This is the part most headlines flattened. Rescheduling is not legalization. Schedule III substances are still controlled — they're regulated prescription-type substances, not free-for-alls. And crucially, the April order did not touch adult-use, recreational cannabis, which is what the vast majority of a Vermont shop's shelf actually is. That product remains on Schedule I under federal law.
Synthetic THC also stays on Schedule I. So the move carved out a defined category — federally recognized medical and FDA-approved marijuana — and left the rest where it was, at least for now.
What's still being decided?
The rest of the question — whether to reschedule marijuana more broadly, including the adult-use side — went to a separate DEA administrative hearing. Per the reporting around the process, that hearing began June 29, 2026 and was scheduled to conclude around July 15, 2026. A hearing is not a decision: it's the formal, on-the-record step where evidence gets weighed before the DEA rules. As of this writing there is no final outcome on that broader piece, and timelines in administrative proceedings routinely slip.
The honest summary is: one narrow, defined category moved in April; the big, market-wide question is still working its way through the process. Anyone telling you recreational cannabis is now federally legal is getting ahead of the facts.
Does any of this change what I pay or how I shop in Vermont?
For a walk-in adult-use customer in Burlington, no. Vermont's cannabis market runs on state law and the rules of the Vermont Cannabis Control Board (CCB) — and none of that is set by the federal schedule. So your trip looks identical to last month:
- Still 21+ with a valid photo ID, every visit.
- Still taxed the same. Vermont's 14% cannabis excise tax and 6% sales tax still apply — roughly 20% statewide, and 21% here in Burlington once the city's 1% local option is added. The full breakdown is in our guide to what you actually pay in Vermont cannabis tax.
- Still no public consumption. Cannabis is for private use at home only — not on Church Street, the waterfront, or in a parked car. That's unchanged.
- Still can't cross state lines, even into a neighboring legal state. Interstate transport remains off-limits.
- Still Vermont-grown and lab-tested on a licensed shelf — the whole reason to buy licensed rather than gray-market.
The federal reschedule is a change in how Washington classifies a category of cannabis. It is not a change to Vermont's purchase limits, taxes, IDs, or where you can legally use what you buy.
If it doesn't change my receipt, why does it matter?
Because the biggest effects land on the business and research side, not the checkout counter. Two stand out:
Federal taxes on cannabis companies. A federal tax rule known as 280E has long barred businesses that traffic in Schedule I or II substances from deducting ordinary expenses like rent and payroll — an unusually heavy tax burden. Products that move to Schedule III fall outside that rule. That's a meaningful shift for the parts of the industry the reschedule covers, though it doesn't automatically translate into lower shelf prices, and the adult-use side is still under Schedule I.
Research. Schedule I status made legitimate scientific study of cannabis famously difficult. A lower schedule generally makes federally sanctioned research easier to conduct — which, over years, tends to produce better data for regulators and health professionals to work from.
How does this connect to Vermont's medical-use endorsement?
This trips people up, because both stories carry the word "medical" — but they're on completely different layers. The federal reschedule is Washington reclassifying a category under national drug law. Vermont's medical-use endorsement is a state program run by the CCB that lets an adult-use shop serve registered Vermont patients tax-free. One is federal; one is state. Neither one created or depends on the other.
If you're a registered patient, the concrete, dollars-and-cents benefit in Vermont still comes from the state endorsement — not the federal schedule. We walk through exactly who qualifies and how the tax exemption works in our guide to Vermont's medical-use endorsement. If you're shopping adult-use, none of the medical machinery — state or federal — touches your visit.
What should a Vermont shopper actually do with this news?
Mostly, nothing — and that's the point. It's a big, genuinely historic move in federal drug policy, and it's worth understanding. But it doesn't ask anything of you at the shop. A few things worth keeping straight:
- Don't assume recreational cannabis is federally legal. It isn't — the April order left adult-use on Schedule I.
- Don't expect your Vermont taxes or limits to change because of a federal reschedule. They're set by state law and the CCB.
- Watch the primary sources, not the hot takes. The DOJ's announcement and the Federal Register notice are the record; the broader DEA question is still in process.
- Keep doing the basics — 21+, ID every time, private consumption at home, keep your receipt and sealed packaging.
When you're ready to shop, the experience is the same as it's always been: browse the live menu, and if it's your first visit, our first-time Burlington dispensary walkthrough covers the whole flow. The law above the shelf moved a little; the shelf itself didn't.
